Literature DB >> 10915630

Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis.

M J Arthur1.   

Abstract

Liver fibrosis is characterized by activation of hepatic stellate cells, which are then involved in synthesis of matrix proteins and in regulating matrix degradation. In the acute phases of liver injury and as liver fibrosis progresses, there is increased expression of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). Among the changes described, striking features include increased expression of gelatinase A (MMP-2) and membrane type 1-MMP (MT(1)-MMP; MMP-14) as well as TIMP-1 and TIMP-2. These molecules and other family members are involved in regulating degradation of both normal and fibrotic liver matrix. This article outlines recent progress in this field and discusses the mechanisms by which MMPs and TIMPs may contribute to the progression and regression of liver fibrosis. Recently described properties of MMPs and TIMPs of relevance to the pathogenesis of liver fibrosis are outlined. The proposal that regression of liver fibrosis is mediated by decreased expression of TIMPs and involves degradation of fibrillar collagens by a combination of MT(1)-MMP and gelatinase A, in addition to interstitial collagenase, is explored.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10915630     DOI: 10.1152/ajpgi.2000.279.2.G245

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  130 in total

1.  Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 expression in fibrotic rat liver.

Authors:  Hai-Lin Liu; Xuan-Hai Li; Dan-Yi Wang; Shao-Ping Yang
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

2.  "Liverscore" is predictive of both liver fibrosis and activity in chronic hepatitis C.

Authors:  Shoukat Ali Arain; Qamar Jamal; Amir Omair
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

3.  Modulation of AP-endonuclease1 levels associated with hepatic cirrhosis in rat model treated with human umbilical cord blood mononuclear stem cells.

Authors:  Ahmad R Bassiouny; Amira Z Zaky; Shaymaa A Abdulmalek; Kamal M Kandeel; Alaa Ismail; Marie Moftah
Journal:  Int J Clin Exp Pathol       Date:  2011-10-16

Review 4.  Clinical implications of matrix metalloproteinases.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Chakraborti Sajal
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

Review 5.  Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases.

Authors:  Takayuki Shiomi; Vincent Lemaître; Jeanine D'Armiento; Yasunori Okada
Journal:  Pathol Int       Date:  2010-07       Impact factor: 2.534

Review 6.  Targeting Hepatic Fibrosis in Autoimmune Hepatitis.

Authors:  Aldo J Montano-Loza; Ragesh B Thandassery; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199

7.  The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis.

Authors:  Haiyan Jin; Shuji Terai; Isao Sakaida
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

8.  Leptin increases tissue inhibitor of metalloproteinase I (TIMP-1) gene expression by a specificity protein 1/signal transducer and activator of transcription 3 mechanism.

Authors:  Songbai Lin; Neeraj K Saxena; Xiaokun Ding; Lance L Stein; Frank A Anania
Journal:  Mol Endocrinol       Date:  2006-08-24

9.  Matrix metalloproteinase (MMP)-3 polymorphism in patients with HBV related chronic liver disease.

Authors:  Hyun Phil Shin; Joung Il Lee; Joo-Ho Jung; Sung-Vin Yim; Hyun Jeong Kim; Jae Myung Cha; Jong Beom Park; Kwang Ro Joo; Jae Seok Hwang; Byoung-Kuk Jang
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

10.  Apoptosis of rat hepatic stellate cells induced by anti-focal adhesion kinase antibody.

Authors:  Xiao-Jing Liu; Li Yang; Hong-Bin Wu; Ou Qiang; Ming-Hui Huang; Ying-Ping Wang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.